Sukumar Nagendran Sells 1,780 Shares of AveXis, Inc. (AVXS) Stock
AveXis, Inc. (NASDAQ:AVXS) VP Sukumar Nagendran sold 1,780 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $94.77, for a total transaction of $168,690.60. Following the sale, the vice president now directly owns 1,780 shares in the company, valued at $168,690.60. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Sukumar Nagendran also recently made the following trade(s):
- On Wednesday, November 1st, Sukumar Nagendran sold 1,780 shares of AveXis stock. The stock was sold at an average price of $101.26, for a total transaction of $180,242.80.
- On Monday, October 2nd, Sukumar Nagendran sold 1,780 shares of AveXis stock. The stock was sold at an average price of $97.25, for a total transaction of $173,105.00.
AveXis, Inc. (AVXS) traded down $1.53 during trading on Thursday, hitting $91.97. 313,300 shares of the company were exchanged, compared to its average volume of 425,783. AveXis, Inc. has a 52 week low of $44.68 and a 52 week high of $108.27.
AveXis (NASDAQ:AVXS) last released its earnings results on Thursday, November 9th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.48) by ($0.04). During the same quarter in the prior year, the business posted ($0.87) EPS. research analysts expect that AveXis, Inc. will post -6.23 earnings per share for the current fiscal year.
Institutional investors have recently added to or reduced their stakes in the stock. Strs Ohio acquired a new position in shares of AveXis during the 3rd quarter valued at $116,000. Botty Investors LLC acquired a new position in shares of AveXis during the 2nd quarter valued at $123,000. Cubist Systematic Strategies LLC lifted its position in shares of AveXis by 688.6% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock valued at $175,000 after acquiring an additional 1,577 shares during the period. Teacher Retirement System of Texas acquired a new position in shares of AveXis during the 3rd quarter valued at $200,000. Finally, Deschutes Portfolio Strategy LLC acquired a new position in shares of AveXis during the 3rd quarter valued at $203,000. Institutional investors own 92.88% of the company’s stock.
AVXS has been the topic of a number of research reports. BMO Capital Markets reissued a “buy” rating and set a $123.00 target price on shares of AveXis in a report on Friday, August 11th. Bank of America reduced their price objective on shares of AveXis from $115.00 to $112.00 and set a “buy” rating on the stock in a research note on Friday, November 10th. Morgan Stanley reaffirmed an “overweight” rating and issued a $118.00 price objective on shares of AveXis in a research note on Wednesday, August 9th. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $134.00 price objective (up from $89.00) on shares of AveXis in a research note on Tuesday, September 5th. Finally, Evercore ISI initiated coverage on shares of AveXis in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $120.00 price objective on the stock. Three analysts have rated the stock with a sell rating, three have issued a hold rating and thirteen have given a buy rating to the stock. AveXis has a consensus rating of “Buy” and an average price target of $110.67.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.